Our proprietary molecular PCR reagents were strategically crafted with the intention to create a clinically superior offering that was financially sustainable for the "long-haul", all processed on one economical machine. 

​

In today's volatile market of ever-changing reimbursement, patient behavioral patterns, new technologies and M&A transactions, our proprietary technology minimizes risk of investment in order to thrive during all aforementioned market challenges.

​

With on-site validation studies run for every single organism on every single panel, our technology boasts 99% or higher accuracy, specificity, sensitivity and precision.

​

Outfitted on a common, "workhorse"-type thermal cycler, our proprietary PCR reagents have proven to provide for an elevation of patient care, an increase in laboratory and clinic efficiencies, as well as dramatically boosting positive revenue cycles.

​

​